TABLE OF CONTENTS
1 INTRODUCTION 84
1.1 OBJECTIVES OF THE STUDY 84
1.2 MARKET DEFINITION 84
1.3 OVERVIEW OF THE NORTH AMERICA DYSPEPSIA DRUG MARKET 84
1.4 CURRENCY AND PRICING 86
1.5 LIMITATIONS 86
1.6 MARKETS COVERED 86
2 MARKET SEGMENTATION 90
2.1 MARKETS COVERED 90
2.2 GEOGRAPHICAL SCOPE 91
2.3 YEARS CONSIDERED FOR THE STUDY 92
2.4 DBMR TRIPOD DATA VALIDATION MODEL 93
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 96
2.6 MULTIVARIATE MODELLING 97
2.7 TYPE LIFELINE CURVE 97
2.8 DBMR MARKET POSITION GRID 98
2.9 VENDOR SHARE ANALYSIS 100
2.10 MARKET END-USER COVERAGE GRID 101
2.11 SECONDARY SOURCES 102
2.12 ASSUMPTIONS 102
3 EXECUTIVE SUMMARY 103
4 PREMIUM INSIGHT 106
4.1 PESTEL ANALYSIS 107
4.2 PORTERS FIVE FORCES 108
5 EPIDEMIOLOGY 109
6 PROBLEMS IN THE MANAGEMENT OF DYSPEPSIA 110
7 INDUSTRY INSIGHTS: 111
8 NORTH AMERICA DYSPEPSIA DRUG MARKET, REGULATION 112
9 MARKET OVERVIEW 115
9.1 DRIVERS 117
9.1.1 INCREASING PREVALENCE OF DYSPEPSIA 117
9.1.2 RISE IN THE ADOPTION OF UNHEALTHY LIFESTYLE 117
9.1.3 INCREASE IN THE PREVALENCE OF METABOLIC DISORDERS 118
9.2 RESTRAINTS 119
9.2.1 POSSIBLE SIDE EFFECTS OF THE DRUGS USED FOR DYSPEPSIA 119
9.2.2 INCREASING PREFERENCE FOR NATURAL AND HERBAL REMEDIES 120
9.3 OPPORTUNITIES 120
9.3.1 GROWING AGING POPULATION 120
9.3.2 RISE IN THE DRUG APPROVAL 121
9.4 CHALLENGES 122
9.4.1 LACK OF AWARENESS ABOUT DYSPEPSIA AMONG THE POPULATION 122
9.4.2 STRINGENT REGULATIONS 122
10 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY TYPE 123
10.1 OVERVIEW 124
10.2 NON-ULCER DYSPEPSIA 127
10.3 ORGANIC DYSPEPSIA 127
10.4 DRUG INDUCED DYSPEPSIA 128
10.5 OTHERS 129
11 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE 130
11.1 OVERVIEW 131
11.2 MEDICATION 134
11.2.1 DRUGS 135
11.2.1.1 ANTACIDS 135
11.2.1.1.1 PROTON PUMP INHIBITORS (PPIS) 135
11.2.1.1.1.1 OMEPRAZOLE 136
11.2.1.1.1.2 LANSOPRAZOLE 136
11.2.1.1.1.3 ESOMEPRAZOLE 136
11.2.1.1.1.4 OTHERS 136
11.2.1.1.2 H2 BLOCKERS 136
11.2.1.1.2.1 CIMETIDINE 137
11.2.1.1.2.2 FAMOTIDINE 137
11.2.1.1.2.3 NIZATIDINE 137
11.2.1.1.2.4 RANITIDINE 137
11.2.1.1.2.5 OTHERS 137
11.2.1.2 GASTRIC PROKINETIC GENDERNTS 137
11.2.1.2.1 MOSAPRIDE CITRATE 138
11.2.1.2.2 METOCLOPRAMIDE 138
11.2.1.2.3 CISAPRIDE 138
11.2.1.2.4 ITOPRIDE HYDROCHLORIDE 138
11.2.1.2.5 DOMPERIDONE 138
11.2.1.2.6 OTHERS 139
11.2.1.3 ANTIBIOTICS 139
11.2.1.3.1 REFAXIMIN 139
11.2.1.3.2 AMOXICILLIN 139
11.2.1.3.3 CLARITHROMYCIN 139
11.2.1.3.4 METRONIDAZOLE 140
11.2.1.3.5 LEVOFLOXACIN 140
11.2.1.3.6 TETRACYCLINE 140
11.2.1.3.7 OTHERS 140
11.2.1.4 OTHERS 140
11.2.2 NON- DRUGS 140
11.2.2.1 PROBIOTICS 140
11.2.2.1.1 LACTOBACILLUS 141
11.2.2.1.2 BIFIDOBACTERIUM 141
11.2.2.1.3 BACILLUS 141
11.2.2.1.4 STREPTOCOCCUS 141
11.2.2.1.5 OTHERS 141
11.2.2.2 PREBIOTICS 141
11.3 SURGERY 142
12 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY DRUG TYPE 143
12.1 OVERVIEW 144
12.2 GENERIC 147
12.3 BRANDED 148
13 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY PRESCRIPTION 149
13.1 OVERVIEW 150
13.2 WITHOUT PRESCRIPTION DRUGS 153
13.3 PRESCRIPTION DRUGS 154
14 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION 155
14.1 OVERVIEW 156
14.2 ORAL 159
14.2.1 TABLETS 159
14.2.2 CAPSULES 160
14.3 INJECTABLE 160
15 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY GENDER 161
15.1 OVERVIEW 162
15.2 FEMALE 165
15.2.1 30-50 YEARS 166
15.2.2 MORE THAN 50 YEARS 166
15.2.3 AGE LESS THAN 30 166
15.3 MALE 166
15.3.1 30-50 YEARS 167
15.3.2 MORE THAN 50 YEARS 167
15.3.3 AGE LESS THAN 30 167
16 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY END USER 168
16.1 OVERVIEW 169
16.2 HOSPITALS 172
16.2.1 TYPE 172
16.2.1.1 PUBLIC 173
16.2.1.2 PRIVATE 173
16.2.2 TIER 173
16.2.2.1 TIER 3 173
16.2.2.2 TIER 2 173
16.2.2.3 TEIR 1 173
16.3 CLINICS 173
16.4 HOMECARE SETTINGS 174
16.5 SPECIALTY CLINICS 175
16.6 AMBULATORY CENTERS 176
16.7 ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES 176
16.8 OTHERS 177
17 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL 178
17.1 OVERVIEW 179
17.2 RETAIL SALES 182
17.2.1 REATIL PHARMACY 183
17.2.2 HOSPITAL PHARMACY 183
17.2.3 ONLINE PHARMACY 183
17.3 DIRECT TENDER 183
18 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY REGION 184
18.1 NORTH AMERICA 185
18.1.1 U.S. 198
18.1.2 CANADA 206
18.1.3 MEXICO 215
19 NORTH AMERICA DYSPEPSIA DRUG MARKET, COMPANY LANDSCAPE 224
19.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 224
20 SWOT ANALYSIS 225
21 NORTH AMERICA DYSPEPSIA DRUG MARKET, COMPANY PROFILINGS 226
21.1 SANOFI 226
21.1.1 COMPANY SNAPSHOT 226
21.1.2 REVENUE ANALYSIS 226
21.1.3 COMPANY SHARE ANALYSIS 227
21.1.4 PRODUCT PORTFOLIO 227
21.1.5 RECENT DEVELOPMENT 227
21.2 LUPIN 228
21.2.1 COMPANY SNAPSHOT 228
21.2.2 REVENUE ANALYSIS 228
21.2.3 COMPANY SHARE ANALYSIS 229
21.2.4 PRODUCT PORTFOLIO 229
21.2.5 RECENT DEVELOPMENTS 229
21.3 MANKIND PHARMA 230
21.3.1 COMPANY SNAPSHOT 230
21.3.2 REVENUE ANALYSIS 230
21.3.3 COMPANY SHARE ANALYSIS 231
21.3.4 PRODUCT PORTFOLIO 231
21.3.5 RECENT DEVELOPMENT 231
21.4 ASTRAZENECA 232
21.4.1 COMPANY SNAPSHOT 232
21.4.2 REVENUE ANALYSIS 232
21.4.3 COMPANY SHARE ANALYSIS 233
21.4.4 PRODUCT PORTFOLIO 233
21.4.5 RECENT DEVELOPMENT 233
21.5 BAYER AG 234
21.5.1 COMPANY SNAPSHOT 234
21.5.2 REVENUE ANALYSIS 234
21.5.3 COMPANY SHARE ANALYSIS 235
21.5.4 PRODUCT PORTFOLIO 235
21.5.5 RECENT DEVELOPMENT 235
21.6 ABBOTT 236
21.6.1 COMPANY SNAPSHOT 236
21.6.2 REVENUE ANALYSIS 236
21.6.3 PRODUCT PORTFOLIO 237
21.6.4 RECENT DEVELOPMENT 237
21.7 ANI PHARMACEUTICALS, INC. 238
21.7.1 COMPANY SNAPSHOT 238
21.7.2 REVENUE ANALYSIS 238
21.7.3 PRODUCT PORTFOLIO 239
21.7.4 RECENT DEVELOPMENT 239
21.8 AOSAIKANG PHARMACEUTICAL CO., LTD. 240
21.8.1 COMPANY SNAPSHOT 240
21.8.2 REVENUE ANALYSIS 240
21.8.3 PRODUCT PORTFOLIO 241
21.8.4 RECENT DEVELOPMENT 241
21.9 ASTERISK LABORATORIES (I) PVT. LTD 242
21.9.1 COMPANY SNAPSHOT 242
21.9.2 PRODUCT PORTFOLIO 242
21.9.3 RECENT DEVELOPMENT 242
21.10 CADILA PHARMACEUTICALS 243
21.10.1 COMPANY SNAPSHOT 243
21.10.2 REVENUE ANALYSIS 243
21.10.3 COMPANY SHARE ANALYSIS 244
21.10.4 PRODUCT PORTFOLIO 244
21.10.5 RECENT DEVELOPMENT 244
21.11 HANMI PHARM. CO., LTD. 245
21.11.1 COMPANY SNAPSHOT 245
21.11.2 REVENUE ANALYSIS 245
21.11.3 PRODUCT PORTFOLIO 246
21.11.4 RECENT DEVELOPMENT 246
21.12 MCNEIL CONSUMER PHARMACEUTICALS CO. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.) 247
21.12.1 COMPANY SNAPSHOT 247
21.12.2 REVENUE ANALYSIS 247
21.12.3 PRODUCT PORTFOLIO 248
21.12.4 RECENT DEVELOPMENT 248
21.13 OTSUKA PHARMACEUTICAL CO., LTD. 249
21.13.1 COMPANY SNAPSHOT 249
21.13.2 REVENUE ANALYSIS 249
21.13.3 PRODUCT PORTFOLIO 250
21.13.4 RECENT DEVELOPMENT 250
21.14 PERRIGO COMPANY PLC 251
21.14.1 COMPANY SNAPSHOT 251
21.14.2 REVENUE ANALYSIS 251
21.14.3 PRODUCT PORTFOLIO 252
21.14.4 RECENT DEVELOPMENT 252
21.15 PRESTIGE CONSUMER HEALTHCARE, INC. 253
21.15.1 COMPANY SNAPSHOT 253
21.15.2 REVENUE ANALYSIS 253
21.15.3 PRODUCT PORTFOLIO 254
21.15.4 RECENT DEVELOPMENT 254
21.16 PROCTER & GAMBLE 255
21.16.1 COMPANY SNAPSHOT 255
21.16.2 REVENUE ANALYSIS 255
21.16.3 PRODUCT PORTFOLIO 256
21.16.4 RECENT DEVELOPMENT 256
21.17 RECKITT BENCKISER. 257
21.17.1 COMPANY SNAPSHOT 257
21.17.2 REVENUE ANALYSIS 257
21.17.3 PRODUCT PORTFOLIO 258
21.17.4 RECENT DEVELOPMENT 258

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.